Summary
McKesson Corporation's (MCK) 10-Q filing for the period ending December 31, 2011, demonstrates robust revenue growth, primarily driven by its Distribution Solutions segment. The company reported a significant increase in both quarterly and year-to-date revenues, reflecting market growth and the positive impact of the US Oncology acquisition. Despite facing ongoing litigation charges, particularly related to Average Wholesale Price (AWP) claims, McKesson has shown improved profitability from continuing operations, with diluted earnings per share seeing substantial year-over-year growth. The balance sheet indicates a healthy increase in cash and cash equivalents and total assets, supported by growing inventory and receivables. The company continues to actively manage its capital structure, with substantial share repurchase programs in place. McKesson also provided an update on its European operations with a subsequent event announcing the agreement to acquire certain Canadian assets, signaling continued strategic expansion. Overall, the filing presents a company experiencing top-line growth with improving operational performance, albeit with persistent legal contingencies requiring careful monitoring.
Financial Highlights
53 data points| Revenue | $30.84B |
| Cost of Revenue | $29.27B |
| Gross Profit | $1.57B |
| Operating Expenses | $1.07B |
| Operating Income | $492.00M |
| Net Income | $300.00M |
| EPS (Basic) | $1.22 |
| EPS (Diluted) | $1.20 |
| Shares Outstanding (Basic) | 246.00M |
| Shares Outstanding (Diluted) | 251.00M |
Key Highlights
- 1Revenues grew 9% year-over-year for both the quarter and the nine-month period, reaching $30.8 billion and $91.0 billion, respectively, primarily driven by the Distribution Solutions segment.
- 2Income from continuing operations saw a substantial increase, up 94% for the quarter to $300 million and 25% year-to-date to $882 million.
- 3Diluted Earnings Per Share (EPS) from continuing operations more than doubled year-over-year for the quarter, reaching $1.20, and increased 30% year-to-date to $3.51.
- 4The company's cash and cash equivalents increased to $4.19 billion from $3.61 billion, indicating strong cash generation.
- 5McKesson is actively returning capital to shareholders, with significant share repurchase programs in place, totaling $1.5 billion in authorizations.
- 6The company reported a substantial reserve of $449 million for its Average Wholesale Price (AWP) litigation as of December 31, 2011, though litigation charges decreased significantly compared to the prior year.
- 7A subsequent event announced an agreement to acquire Drug Trading Company Limited and Medicine Shoppe Canada Inc. for approximately CAD $920 million, signaling continued strategic growth in Canada.